FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280608238> ?p ?o ?g. }

• W4280608238 endingPage "103634" @default.
• W4280608238 startingPage "103634" @default.
• W4280608238 abstract "Background: Patient-reported outcomes (PROs) is a useful way to determine the various effects of disease modifying therapy (DMT) on patients daily lives and their disease course. This study aimed to evaluate the patients’ treatment satisfaction after switching to a brand-generic Teriflunomide product (Tebazio®, 14 mg tablet) produced by Zistdaru Danesh biopharmaceutical company and report the tolerability and safety concerns during the period of the treatment.Material(s) and Method(s): The study was conducted on patients with confirmed diagnosis of multiple sclerosis (MS) as defined by the Revised McDonald Criteria (2015) from Nov 2019 to Nov 2020. They were ambulatory with a EDSS of 0 to 5.5, and their treatment by Teriflunomide 14 mg was just started. Study outcomes included patients’ satisfaction was measured by Treatment Satisfaction Questionnaire for Medication [Version 1.4] (TSQM) at baseline and week 24, disability status measured by Expanded Disability Status Scale [EDSS] score at baseline and week 24, safety and tolerability evaluated over 6 months.Result(s): Of 200 patients enrolled, 100 patients completed the study protocol and evaluated. Patients reported significant improvements in treatment satisfaction scores of convenience and side effects domains of TSQM scores at week 24 following the switch to teriflunomide (Effectiveness: baseline, 66.53, Week 24, 68.97; Convenience: baseline, 66.31, Week 24, 78.97; Side effect: baseline, 67.13, Week 24, 75.60; Overall Satisfaction: baseline, 63 Week 24, 65.42; P < 0.001 in all comparisons). The most common adverse drug reactions were hair thinning (36%), dermatologic (17%), gastrointestinal (23%), liver function test (LFT) dysfunction (11%), and neurologic side effects (9%) which rarely caused treatment discontinuation.Conclusion(s): Patients reported significant satisfaction regarding TSQM scores after switching to Tebazio at week 24 which can be impressive to increase patient compliance. The 14 mg brand-generic Teriflunomide product was well tolerated in Iranian RRMS patients and no new alarming signal was detected during the study period. Background: Patient-reported outcomes (PROs) is a useful way to determine the various effects of disease modifying therapy (DMT) on patients daily lives and their disease course. This study aimed to evaluate the patients’ treatment satisfaction after switching to a brand-generic Teriflunomide product (Tebazio®, 14 mg tablet) produced by Zistdaru Danesh biopharmaceutical company and report the tolerability and safety concerns during the period of the treatment. Material(s) and Method(s): The study was conducted on patients with confirmed diagnosis of multiple sclerosis (MS) as defined by the Revised McDonald Criteria (2015) from Nov 2019 to Nov 2020. They were ambulatory with a EDSS of 0 to 5.5, and their treatment by Teriflunomide 14 mg was just started. Study outcomes included patients’ satisfaction was measured by Treatment Satisfaction Questionnaire for Medication [Version 1.4] (TSQM) at baseline and week 24, disability status measured by Expanded Disability Status Scale [EDSS] score at baseline and week 24, safety and tolerability evaluated over 6 months. Result(s): Of 200 patients enrolled, 100 patients completed the study protocol and evaluated. Patients reported significant improvements in treatment satisfaction scores of convenience and side effects domains of TSQM scores at week 24 following the switch to teriflunomide (Effectiveness: baseline, 66.53, Week 24, 68.97; Convenience: baseline, 66.31, Week 24, 78.97; Side effect: baseline, 67.13, Week 24, 75.60; Overall Satisfaction: baseline, 63 Week 24, 65.42; P < 0.001 in all comparisons). The most common adverse drug reactions were hair thinning (36%), dermatologic (17%), gastrointestinal (23%), liver function test (LFT) dysfunction (11%), and neurologic side effects (9%) which rarely caused treatment discontinuation. Conclusion(s): Patients reported significant satisfaction regarding TSQM scores after switching to Tebazio at week 24 which can be impressive to increase patient compliance. The 14 mg brand-generic Teriflunomide product was well tolerated in Iranian RRMS patients and no new alarming signal was detected during the study period." @default.
• W4280608238 created "2022-05-22" @default.
• W4280608238 creator A5017247111 @default.
• W4280608238 creator A5026255529 @default.
• W4280608238 creator A5040626637 @default.
• W4280608238 creator A5041503753 @default.
• W4280608238 creator A5046282061 @default.
• W4280608238 creator A5049834232 @default.
• W4280608238 creator A5050527788 @default.
• W4280608238 creator A5066660617 @default.
• W4280608238 creator A5079526892 @default.
• W4280608238 date "2022-03-01" @default.
• W4280608238 modified "2023-10-16" @default.
• W4280608238 title "Patient Reported Outcomes of New Brand-Generic Product of Teriflunomide in Patients with Relapsing-Remitting Multiple Sclerosis: Preliminary Analysis" @default.
• W4280608238 doi "https://doi.org/10.1016/j.msard.2022.103634" @default.
• W4280608238 hasPublicationYear "2022" @default.
• W4280608238 type Work @default.
• W4280608238 citedByCount "0" @default.
• W4280608238 crossrefType "journal-article" @default.
• W4280608238 hasAuthorship W4280608238A5017247111 @default.
• W4280608238 hasAuthorship W4280608238A5026255529 @default.
• W4280608238 hasAuthorship W4280608238A5040626637 @default.
• W4280608238 hasAuthorship W4280608238A5041503753 @default.
• W4280608238 hasAuthorship W4280608238A5046282061 @default.
• W4280608238 hasAuthorship W4280608238A5049834232 @default.
• W4280608238 hasAuthorship W4280608238A5050527788 @default.
• W4280608238 hasAuthorship W4280608238A5066660617 @default.
• W4280608238 hasAuthorship W4280608238A5079526892 @default.
• W4280608238 hasBestOaLocation W42806082381 @default.
• W4280608238 hasConcept C118552586 @default.
• W4280608238 hasConcept C126322002 @default.
• W4280608238 hasConcept C141071460 @default.
• W4280608238 hasConcept C1862650 @default.
• W4280608238 hasConcept C197934379 @default.
• W4280608238 hasConcept C2775944032 @default.
• W4280608238 hasConcept C2776036978 @default.
• W4280608238 hasConcept C2777703276 @default.
• W4280608238 hasConcept C2778375690 @default.
• W4280608238 hasConcept C2779134260 @default.
• W4280608238 hasConcept C2780640218 @default.
• W4280608238 hasConcept C2780892749 @default.
• W4280608238 hasConcept C3020694758 @default.
• W4280608238 hasConcept C71924100 @default.
• W4280608238 hasConceptScore W4280608238C118552586 @default.
• W4280608238 hasConceptScore W4280608238C126322002 @default.
• W4280608238 hasConceptScore W4280608238C141071460 @default.
• W4280608238 hasConceptScore W4280608238C1862650 @default.
• W4280608238 hasConceptScore W4280608238C197934379 @default.
• W4280608238 hasConceptScore W4280608238C2775944032 @default.
• W4280608238 hasConceptScore W4280608238C2776036978 @default.
• W4280608238 hasConceptScore W4280608238C2777703276 @default.
• W4280608238 hasConceptScore W4280608238C2778375690 @default.
• W4280608238 hasConceptScore W4280608238C2779134260 @default.
• W4280608238 hasConceptScore W4280608238C2780640218 @default.
• W4280608238 hasConceptScore W4280608238C2780892749 @default.
• W4280608238 hasConceptScore W4280608238C3020694758 @default.
• W4280608238 hasConceptScore W4280608238C71924100 @default.
• W4280608238 hasLocation W42806082381 @default.
• W4280608238 hasOpenAccess W4280608238 @default.
• W4280608238 hasPrimaryLocation W42806082381 @default.
• W4280608238 hasRelatedWork W1871570547 @default.
• W4280608238 hasRelatedWork W1982594744 @default.
• W4280608238 hasRelatedWork W1987365422 @default.
• W4280608238 hasRelatedWork W2001155665 @default.
• W4280608238 hasRelatedWork W2020206181 @default.
• W4280608238 hasRelatedWork W2148147073 @default.
• W4280608238 hasRelatedWork W2971309441 @default.
• W4280608238 hasRelatedWork W3006577702 @default.
• W4280608238 hasRelatedWork W3113951574 @default.
• W4280608238 hasRelatedWork W4367303736 @default.
• W4280608238 hasVolume "59" @default.
• W4280608238 isParatext "false" @default.
• W4280608238 isRetracted "false" @default.
• W4280608238 workType "article" @default.